Pharmaceutical - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

201 to 225 of 400 results

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Brazil to resume human insulin production, with a $200+ investment

18-04-2013

The resumption of national human insulin production was announced in Brazil this week, at an event in…

Biomm TechnologyDiabetesFiocruzInsulinPharmaceuticalProductionSouth America

Lilly's diabetes drug dulaglutide does well in two additional trials

16-04-2013

US drug major Eli Lilly (NYSE: LLY) has released positive top-line results of two additional Phase III…

DiabetesdulaglutideEli LillyPharmaceuticalResearch

Eli Lilly views additional $180 million investment to expand insulin making in Indianapolis

02-04-2013

US pharma major Eli Lilly (NYSE: LLY) says that it is working closely with the City on a proposal to…

DiabetesFinancialInsulinLillyNorth AmericaPharmaceuticalProduction

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

EMA follows FDA lead, launching investigation on pancreatic risks with GLP-1-based type 2 diabetes drugs

27-03-2013

The European Medicines Agency says it is investigating findings by a group of independent academic researchers…

DiabetesEuropePharmaceuticalRegulation

Germany's IQWiG finds no added benefit for AstraZeneca and Bristol-Myers' Forxiga

25-03-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

Merck KGaA links with Bristol-Myers for Glucophage promotion in China

19-03-2013

German drugs and chemicals group Merck KGaA this morning announced a collaboration with US pharma major…

Asia-PacificBristol-Myers SquibbDiabetesGlucophageGlucophage XRLicensingMarkets & MarketingMerck KGaAPharmaceutical

New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 diabetes patients

18-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has released headline results from a 56-week, double-blind…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchVictoza

Astellas files for Japanese approval of ipragliflozin for types 2 diabetes

14-03-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for…

Asia-PacificAstellas PharmaDiabetesipragliflozinPharmaceuticalRegulation

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

11-03-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

Anti-aging breakthrough could mean new drugs within five years

09-03-2013

Drugs that combat aging may be available within five years, following landmark work led by an Australian…

DiabetesGlaxoSmithKlineNeurologicalOncologyPharmaceuticalResearchresveratrol

Novo Nordisk debuts Tresiba in UK and Denmark

04-03-2013

Danish insulin giant Novo Nordisk (NOVN: N) has started the European roll-out of its Tresiba (insulin…

DiabetesEuropeMarkets & MarketingNovo NordiskPharmaceuticalTresiba

Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds

26-02-2013

People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those…

Bristol-Myers SquibbByettaDiabetesJanuviaMerck & CoPharmaceuticalResearch

US FDA accepts Sanofi's NDA for diabetes drug lixisenatide

19-02-2013

The US Food and Drug Administration has accepted for review French drug major Sanofi's (Euronext: SAN)…

DiabeteslixisenatideNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord

13-02-2013

Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg

11-02-2013

Danish insulin giant Novo Nordisk (NOV: N) revealed late Sunday that, on February 8, it received a Complete…

DegludecDiabetesNorth AmericaNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Sanofi's once-daily diabetes drug Lyxumia approved in Europe

04-02-2013

French drug major Sanofi (Euronext: SAN) this morning announced that the European Commission has granted…

DiabetesEuropeLyxumiaPharmaceuticalRegulationSanofi

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

201 to 225 of 400 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top